Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3065
XFOR
X4 Pharmaceuticals, Inc. - Common Stock
4.05 USD-0.49%-2.88%+1.00%+36.36%401.54 M USD
3067
ENTA
Enanta Pharmaceuticals, Inc. - Common Stock
14.08 USD+4.22%-0.49%+10.87%+55.41%410.09 M USD
3097
LXEO
Lexeo Therapeutics, Inc. - Common Stock
4.74 USD+0.85%-6.14%+14.22%-1.04%388.90 M USD
3110
IPSC
Century Therapeutics, Inc. - Common Stock
2.10 USD+3.45%-1.87%+2.44%+346.81%380.26 M USD

Frequently asked questions about Contineum Therapeutics, Inc. Class A Common Stock

What is the Contineum Therapeutics, Inc. Class A Common Stock stock price today?

The current price of Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is 17.04. Over the past 24 hours, the stock has changed by +2.96%. Follow the CTNM chart for real-time price dynamics.

What is the stock ticker of Contineum Therapeutics, Inc. Class A Common Stock?

Contineum Therapeutics, Inc. Class A Common Stock trades under the ticker CTNM. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Contineum Therapeutics, Inc. Class A Common Stock stock going up?

CTNM has changed by +0.41% over the last week, +11.96% over the last month, and +11.59% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Contineum Therapeutics, Inc. Class A Common Stock?

Contineum Therapeutics, Inc. Class A Common Stock currently has a market capitalization of 393.61 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Contineum Therapeutics, Inc. Class A Common Stock earnings last quarter?

Last quarter, Contineum Therapeutics, Inc. Class A Common Stock reported earnings of -0.4 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Contineum Therapeutics, Inc. Class A Common Stock net income for the last quarter?

Contineum Therapeutics, Inc. Class A Common Stock reported net income of -15.15 M for the last quarter. The previous quarter showed -14.46 M, which means net income changed by -4.83%.

How many employees does Contineum Therapeutics, Inc. Class A Common Stock have?

As of the latest available data, Contineum Therapeutics, Inc. Class A Common Stock has 51 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Contineum Therapeutics, Inc. Class A Common Stock stock?

You can buy Contineum Therapeutics, Inc. Class A Common Stock (CTNM) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Contineum Therapeutics, Inc. Class A Common Stock stock?

Investing in Contineum Therapeutics, Inc. Class A Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CTNM chart and related analysis on metatrader.com as part of your research.